Asparkam tab. �56 Renewal

pharmachologic effect

The mechanism of action of the drug Asparkam is associated with the effective participation of L-asparaginate in the transport of magnesium and potassium ions into the intracellular space. Magnesium activates sodium-potassium-ATPase, removing sodium ions from the cell and returning potassium ions

reduces the concentration of sodium and prevents its exchange for calcium in the smooth muscles of blood vessels, lowering their resistance.

Potassium stimulates the synthesis of ATP, glycogen, proteins, acetylcholine, etc. Both ions support the polarization of cell membranes.

The drug regulates the conduction of impulses along nerve fibers, synaptic transmission, muscle contraction, the work of the heart muscle.

Due to magnesium ions, it participates in the processes of energy intake and consumption, normalizes membrane permeability, neuromuscular conductivity, DNA and RNA synthesis, cell growth, cell division, oxygen assimilation and phosphate synthesis.

Pharmacokinetics

Potassium and magnesium ions are rapidly absorbed and distributed throughout all body tissues.

About 30% of magnesium in plasma forms complex compounds with proteins.

The excretion of potassium and magnesium occurs mainly with urine, in small quantities - with feces, sweat, tears, etc. In renal failure, the excretion of potassium and magnesium ions may slow down.

Indications

To eliminate the deficiency of potassium and magnesium

as an aid for various manifestations of coronary heart disease, including acute myocardial infarction

chronic circulatory failure

heart rhythm disturbances (arrhythmias caused by an overdose of cardiac glycosides).

Contraindications

Hypersensitivity to the drug Asparkam,

hyperkalemia,

hypermagnesemia,

acute and chronic renal failure,

insufficiency of the adrenal cortex,

atrioventricular block II and III degree,

cardiogenic shock,

oliguria - anuria,

acute metabolic acidosis,

severe myasthenia gravis,

dehydration, Addison's disease,

arterial hypotension,

pregnancy,

lactation period,

age up to 18 years (efficacy and safety have not been established).

special instructions

No studies have been conducted to assess the effect of the drug on the ability to drive vehicles and engage in other potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions.

Name ENG

ASPARCAM

Clinical and pharmacological group

A drug that replenishes the deficiency of potassium and magnesium in the body

ATX code

Preparations of other mineral substances

Dosage

magnesium asparaginate 175 mg, potassium asparaginate 175 mg

Structure

1 tablet contains: active ingredients: magnesium asparaginate 175 mg, potassium asparaginate 175 mg.

Indications

To eliminate the deficiency of potassium and magnesium

as an aid for various manifestations of coronary heart disease, including acute myocardial infarction

chronic circulatory failure

heart rhythm disturbances (arrhythmias caused by an overdose of cardiac glycosides).

Contraindications

Hypersensitivity to the drug Asparkam,

hyperkalemia,

hypermagnesemia,

acute and chronic renal failure,

insufficiency of the adrenal cortex,

atrioventricular block II and III degree,

cardiogenic shock,

oliguria - anuria,

acute metabolic acidosis,

severe myasthenia gravis,

dehydration, Addison's disease,

arterial hypotension,

pregnancy,

lactation period,

age up to 18 years (efficacy and safety have not been established).

INN / Active ingredient

magnesium asparaginate, potassium asparaginate

Storage conditions and periods

At a temperature not higher than 25 degrees.

Expiration date: 3 years

Specifications

Scope of the drug

Heart, vessels, blood

Release form

Tablet

Manufacturer country

Russia

Package quantity, pcs

56

Minimum age from

18 years

Way of introduction

Through the mouth

Vacation conditions

Without recipe

Brand name

Renewal

The amount of the dosage form in the primary package

8 pcs.

Primary packaging type

Blister

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Potassium and magnesium drug

Anatomical and therapeutic characteristics

A12CX Other mineral preparations

Dosage form

Pills

Expiration date in days

1095

Dosage (volume) of the substance in the preparation

magnesium asparaginate 175 mg, potassium asparaginate 175 mg

Package weight, g

40

Category

:

Cardiovascular disorders

,

Arrhythmia

,

Balance potassium and magnesium

Mode of application

:

Inside, usually for adults - 1-2 tablets 3 times a day after meals.

The course of treatment is 3-4 weeks.

It can be repeated if necessary.